Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol) (CHOROS ORION)

February 12, 2024 updated by: AstraZeneca

Outcomes in Real-life After Initation Of treatmeNt With Trixeo (Budesonide / Glycopyrronium / Formoterol), a Non-interventional, Multi-centre, Prospective Cohort Study in Italian Routine Care Setting

The aim of the CHOROS ORION study is to describe patients' clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation, up to one year of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks of treatment. This will allow to assess the short-term impact of treatment, thus contributing to fill the gap of knowledge from the current available medical literature. Moreover, in order to provide also a broader view, patients will be followed up to 52 weeks, where possible. The study results will be interpreted in the context of an observational study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect.

Study Overview

Detailed Description

The therapeutic goal of chronic obstructive pulmonary disease (COPD) management is mainly reduction of symptoms and severity of exacerbations.Triple therapy (the combination of an ICS, a LABA and a LAMA) in a single fixed-dose combination is a valuable development in the treatment of COPD. On top of treatment adherence enhancement [Gaduzo et al., 2019], trials showed triple therapy improving lung function, Patients-Reported Outcomes (PROs), health-related quality of life, as well as lowering exacerbations and hospitalization rate compared to dual or mono-therapy [Bourbeau et al., 2021; Zheng et al, 2018].

Budesonide/glycopyrrolate/formoterol fumarate, hereafter BGF, is a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The availability of single-inhaler triple therapies in routine care may improve symptoms control, reduce exacerbation rate and COPD-related healthcare costs, thus leading to an improvement in patient health status and quality of life. However, real-world studies focusing on PROs are still limited.

The aim of the CHOROS ORION study is to describe patients' clinical and self-reported outcomes of treatment with BGF in Italy through effectiveness, clinical and self-reported measures assessed pre- and post-treatment initiation, up to one year of observation period. The study will focus primarily on the change in self-perceived health status in the first 12 weeks of treatment. This will allow to assess the short-term impact of treatment, thus contributing to fill the gap of knowledge from the current available medical literature. Moreover, in order to provide also a broader view, patients will be followed up to 52 weeks, where possible. The study results will be interpreted in the context of an observational study design where multiple factors, in addition to the new treatment, may contribute to the treatment effect.

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Acquaviva delle Fonti, Italy
        • Recruiting
        • Research Site
      • Alessandria, Italy
        • Recruiting
        • Research Site
      • Ancona, Italy
        • Recruiting
        • Research Site
      • Avellino, Italy
        • Recruiting
        • Research Site
      • Brescia, Italy
        • Recruiting
        • Research Site
      • Brindisi, Italy
        • Recruiting
        • Research Site
      • Busto Arsizio (Varese), Italy
        • Recruiting
        • Research Site
      • Catania, Italy
        • Recruiting
        • Research Site
      • Cittadella (Padova), Italy
        • Recruiting
        • Research Site
      • Firenze, Italy
        • Recruiting
        • Research Site
      • Foggia, Italy
        • Recruiting
        • Research Site
      • Lecce, Italy
        • Recruiting
        • Research Site
      • Napoli, Italy
        • Recruiting
        • Research Site
      • Passirana (Milano), Italy
        • Recruiting
        • Research Site
      • Pavia, Italy
        • Recruiting
        • Research Site
      • Roma, Italy
        • Recruiting
        • Research Site
      • Torino, Italy
        • Recruiting
        • Research Site
      • Treviso, Italy
        • Recruiting
        • Research Site
      • Verona, Italy
        • Recruiting
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

The study population consists of adult patients with moderate to severe COPD who are eligible for BGF therapy, enrolled consecutively by physicians in specialist setting. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.

Description

Inclusion Criteria:

  1. Male or female, aged >= 40;
  2. Physician-diagnosed COPD;
  3. Signed written informed and privacy consent prior to study participation;
  4. Patients starting treatment with BGF as prescribed according to the label, local market reimbursement criteria, and AIFA Nota 99;
  5. Patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol.

Exclusion Criteria:

  1. COPD due to documented α-1 antitrypsin deficiency;
  2. Patients with controlled COPD treated with triple fixed-dose combination in 12 months prior to screening visits;
  3. Hospitalisation due to COPD exacerbation within the last 30 days prior to enrolment;
  4. Pregnancy or lactation period;
  5. Participation in a non-interventional observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in any interventional, observational or clinical trial in the last 30 days prior to enrolment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
COPD patients
Patients with COPD that start BGF treatment (The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guideline)
BGF is a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LABA and a LAMA. The decision to start treatment with BGF must be made by the treating physician according to the subjects' medical need and a positive benefit/risk balance. The decision to prescribe BGF must be independent of enrolment into the study, must be determined by the treating physician and should be taken according to the standard of current best medical practice and national guidelines.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
COPD Assessment Test (CAT) score
Time Frame: baseline, 12 weeks after treatment start
The change from baseline in COPD Assessment Test (CAT) score after 12 weeks treatment will be analysed using the within person difference between baseline and 12 weeks. Descriptive statistics (mean, median, standard deviation, interquartile range, minimum and maximum) will be provided. The mean change from baseline will be presented along with the 95% CI
baseline, 12 weeks after treatment start

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline features
Time Frame: Baseline
To describe the baseline features of patients starting BGF treatment in a real-world setting, in terms of demographics and clinical characteristics, COPD treatment paths and healthcare resource utilization in the previous year.
Baseline
Impact of COPD on patients' life based on CAT
Time Frame: baseline, 26 and 52 weeks
To describe the impact of COPD on patients' life, and how it changes over time during the observation period of treatment with BGF, administered as per routine clinical practice. COPD Assessment Test (CAT) questionnaire at baseline and after 26 and 52 weeks after BGF treatment start. In case of patient early withdrawal, CAT questionnaire will also be collected at the end of observation.
baseline, 26 and 52 weeks
Patients' satisfaction to BGF
Time Frame: baseline, 26 and 52 weeks
9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) at baseline, 26 and 52 weeks from treatment start. In case of patient early withdrawal, TSQM-9 questionnaire will also be collected at the end of observation.
baseline, 26 and 52 weeks
Patient dyspnoea based on Modified Medical Research Council Dyspnoea Scale (mMRC)
Time Frame: Baseline, 26 and 52 weeks
To describe patient dyspnoea and how it changes over time during the observation period of treatment with BGF, administered as per routine clinical practice. Modified Medical Research Council Dyspnoea Scale (mMRC) questionnaire at baseline, 26 and 52 weeks from treatment start. In case of patient early withdrawal, mMRC questionnaire will also be collected at the end of observation.
Baseline, 26 and 52 weeks
Eosinophil count
Time Frame: baseline, 26 and 52 weeks
To describe the eosinophil count during the observation period of treatment with BGF, administered as per routine clinical practice. Eosinophil count in peripheral blood at baseline visit, and 26- and 52-week visits, which will occur after BGF treatment start, where available.
baseline, 26 and 52 weeks
Responder Rate based on CAT
Time Frame: 12 weeks
To describe the Responder Rate based on the CAT after 12 weeks of initiating treatment with BGF as per routine clinical practice. Number and rate of responders of the CAT [MID=2] after 12 weeks of BGF treatment.
12 weeks
Overall change in health status based on Patient Global Impression of Severity (PGIS) questionnaire
Time Frame: Baseline, 12, 26 and 52 weeks
To assess patient-reported overall change in health status since the start of study treatment and overall global impression of severity during the observation period of treatment with BGF as per routine clinical practice. Single-item patient severity of COPD symptoms using PGIS at baseline, 12, 26 and 52 weeks after BGF treatment start. In case of patient early withdrawal, PGIS questionnaire will also be collected at the end of observation.
Baseline, 12, 26 and 52 weeks
Exacerbation rate
Time Frame: 52 weeks
To describe the occurrence of moderate - severe COPD exacerbations during the observation period of treatment with BGF, administered as per routine clinical practice. Number of moderate - severe COPD exacerbations, occurred during the BGF observation period and Annualized rate of moderate - severe COPD exacerbations during the BGF treatment observation period
52 weeks
Lung function
Time Frame: 52 weeks
Describe Lung function parameters as measured at baseline and 52-week visit, available as per routine clinical practice.
52 weeks
OCS use
Time Frame: 52 weeks
To describe the Oral Corticosteroids (OCS) use during the observation period of treatment with BGF, administered as per routine clinical practice, and in the previous year. OCS use during the observation period after BGF treatment start, and OCS use in the 52 weeks before BGF treatment start.
52 weeks
HCRU
Time Frame: 52 weeks
To describe the healthcare resource utilization related to COPD during the observation period of treatment with BGF, administered as per routine clinical practice, and in the previous year. The number of GP/specialist visits, ER admissions, and hospitalizations (along with duration) related to COPD during the BGF observation period and the 52 weeks prior baseline will be described. The annualised rate of utilization per each type will be calculated.
52 weeks
Safety (frequency of all AEs, SAEs, AEs related to BGF and Special Situations during the observation period)
Time Frame: 52 weeks
To describe safety profile of BGF during the observation period Absolute and relative frequency of all AEs, SAEs, AEs related to BGF and Special Situations during the observation period will be calculated. Moreover, the count of such events will be provided. Descriptive statistics will also be provided for severity, seriousness criteria (where applicable), relation grade with BGF, action taken and outcome.
52 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relation between patient CAT score (dependent variable of interest) and patient baseline characteristics
Time Frame: 52 weeks
To describe the relation of baseline characteristics and the impact of COPD on patients' life during the observation period of treatment with BGF, administered as per routine clinical practice
52 weeks
Baseline variables associated with exacerbations
Time Frame: 52 weeks
To describe the relation of baseline characteristics and occurrence of COPD exacerbations during the observation period of treatment with BGF, administered as per routine clinical practice. The analysis will be performed in steps. Firstly, univariate Poisson regression models for the estimated impact on exacerbations occurrence during the observation period will be estimated independently considering the baseline variables (age, sex, BMI, smoking status, eosinophil count in peripheral blood, COPD phenotype and years from diagnosis, number of previous MACEs, number of moderate - severe COPD exacerbations in the year before BGF treatment start, and OCS use in the year before BGF treatment start). Then a multivariate Poisson regression model will be estimated including relevant variables (i.e. with a significant estimated coefficient), as evaluated through the single univariate regression models and the number of exacerbations during follow up
52 weeks
Occurrence of Major Cardiovascular Events (MACE)
Time Frame: 52 weeks
To describe the occurrence of Major Cardiovascular Events (MACE) during the observation period of treatment with BGF, administered as per routine clinical practice Descriptive statistics of the time to first MACE (cardiovascular death, myocardial infarction, or ischemic stroke) occurred during the BGF treatment observation period will be computed by means of a Kaplan-Meier analysis. In case patients do not experience a MACE, they will be considered as censored observations and time until the end of their observation will be calculated. In addition, the count of MACE and the absolute and relative frequency of patients with a MACE will be calculated during the BGF treatment observation period.
52 weeks
Mortality rate
Time Frame: 52 weeks
To assess the mortality during the observation period of treatment with BGF, administered as per routine clinical practice Descriptive statistics of the time to death occurred during the observation period after BGF treatment start will be computed by means of a Kaplan-Meier analysis. The count of mortality events during the observation period will be reported too.
52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2023

Primary Completion (Estimated)

February 28, 2025

Study Completion (Estimated)

February 28, 2025

Study Registration Dates

First Submitted

May 8, 2023

First Submitted That Met QC Criteria

May 8, 2023

First Posted (Actual)

May 17, 2023

Study Record Updates

Last Update Posted (Estimated)

February 13, 2024

Last Update Submitted That Met QC Criteria

February 12, 2024

Last Verified

February 1, 2024

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

Clinical Trials on BGF (budesonide/glycopyrrolate/formoterol fumarate)

3
Subscribe